Spark Therapeutics Inc. initiated an underwritten public offering of $300 million of its common stock.
The company also intends to grant the underwriters an option to buy up to an additional 15% of the shares offered.
J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Cowen and Co. LLC will act as book-running managers for the offering.